drugset / Trial / NCT02065349

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety

NCT02065349 ↗

Phase 2 Completed 132 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the painkilling efficacy of ASP8477 relative to mock (placebo) in patients that have been diagnosed with painful diabetic peripheral neuropathy or postherpetic neuralgia determined by the change in the average daily pain intensity in patients that initially respond favorably to treatment with ASP8477.

Timeline

Start
2014-02-24
Primary completion
2015-02-13
Completion
2015-02-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator ASP8477 Small molecule — Oral